Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia
Recruiting
Observational Study
Chronic Mesenteric Ischemia
Median Arcuate Ligament Syndrome
Crohn Disease
Cholelithiasis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 180 (estimated)
- Sponsor
- Oslo University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy indi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria: Above 18 years and has given informed written consent for treatment and study participation
For the patient groups :
Group 1: Has CTA or ultrasound diagnosed MALS and is scheduled operative treatment.
Group 2: Has CTA or ultrasound diagnosed CMI and is scheduled operative or e…
Contacts